A second generation cervico-vaginal lavage device shows similar performance as its preceding version with respect to DNA yield and HPV DNA results

BMC Women's Health

Volumn 13, Issue 1, 2013, Pages

  Verhoef, Viola M J ^a   Dijkstra, Maaike G ^a   Bosgraaf, Remko P ^b   Hesselink, Albertus T ^a   Melchers, Willem J G ^b   Bekkers, Ruud L M ^b   Berkhof, Johannes ^a   van Kemenade, Folkert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical screening; HPV DNA testing; Human papillomavirus; Self sampling; Self sampling device

Indexed keywords

DNA; HUMAN PAPILLOMAVIRUS DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ARTICLE; CERVICO VAGINAL LAVAGE DEVICE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; MEDICAL DEVICE; SCREENING; STUDENT T TEST; VAGINAL LAVAGE; WART VIRUS;

ADULT; COHORT STUDIES; EQUIPMENT DESIGN; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; SELF ADMINISTRATION; VAGINAL DOUCHING; VAGINAL SMEARS;

EID: 84878022348     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-13-21     Document Type: Article

References (32)

1. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364:249-256. 10.1016/S0140-6736(04)16674-9, 15262102.
2. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999, 318:904-908. 10.1136/bmj.318.7188.904, 27810, 10102852.
3. Van Ballegooijen M, Van Den Akker Van M, Patnick J, Lynge E, Arbyn M, Anttila A. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000, 36:2177-2188. 10.1016/S0959-8049(00)00330-0, 11072201.
4. Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 1999, 78:478-485. 10.1080/j.1600-0412.1999.780602.x, 10376856.
5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del MA. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257. 10.1016/S1470-2045(09)70360-2, 20089449.
6. Arbyn M, Sanjose SD, Saraiya M, Sideri M, Palefsky J, Lacey C. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012, 131:1969-1982. 10.1002/ijc.27650, 22623137.
7. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13:78-88. 10.1016/S1470-2045(11)70296-0, 22177579.
8. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003, 89:88-93. 10.1038/sj.bjc.6600974, 2394236, 12838306.
9. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006, 119:2372-2375. 10.1002/ijc.22114, 16858676.
10. Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007, 120:1505-1510. 10.1002/ijc.22484, 17205514.
11. Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010, 340:c1040. 10.1136/bmj.c1040, 2837143, 20223872.
12. Gok M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer 2012, 130:1128-1135. 10.1002/ijc.26128, 21484793.
13. Virtanen A, Anttila A, Luostarinen T, Nieminen P. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer 2011, 128:2681-2687. 10.1002/ijc.25581, 20669228.
14. Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011, 20:1960-1969. 10.1158/1055-9965.EPI-11-0307, 21752985.
15. Wikstrom I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 2011, 105:337-339. 10.1038/bjc.2011.236, 3172898, 21730977.
16. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer 2011, 104:915-920. 10.1038/bjc.2011.48, 3065284, 21343937.
17. Giorgi RP, Marsili LM, Camilloni L, Lossa A, Lattanzi A, Sani C. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer 2011, 104:248-254. 10.1038/sj.bjc.6606040, 3031894, 21179038.
18. Holanda F, Castelo A, Veras TM, de Almeida FM, Lins MZ, Dores GB. Primary screening for cervical cancer through self sampling. Int J Gynaecol Obstet 2006, 95:179-184. 10.1016/j.ijgo.2006.07.012, 16997304.
19. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008, 9:929-936. 10.1016/S1470-2045(08)70210-9, 18805733.
20. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmeron J, Uribe P, Velasco-Mondragon E. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011, 378:1868-1873. 10.1016/S0140-6736(11)61522-5, 22051739.
21. Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, Petric M, Chambers K. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 2005, 81:207-212. 10.1136/sti.2004.011858, 1744976, 15923286.
22. Stewart DE, Gagliardi A, Johnston M, Howlett R, Barata P, Lewis N. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J Obstet Gynaecol Can 2007, 29:817-828.
23. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007, 105:530-535. 10.1016/j.ygyno.2007.01.023, 17335880.
24. Schmeink CE, Bekkers RL, Massuger LF, Melchers WJ. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 2011, 21:139-153. 10.1002/rmv.686, 21538664.
25. Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, Van KF. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006, 44:2518-2523. 10.1128/JCM.02440-05, 1489519, 16825374.
26. Dijkstra MG, Heideman DA, Van Kemenade FJ, Hogewoning KJ, Hesselink AT, Verkuijten MC. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. J Clin Virol 2012, 54:147-151. 10.1016/j.jcv.2012.02.022, 22445557.
27. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer 2012, 130:1855-1860. 10.1002/ijc.26202, 21630255.
28. Jolijn Coebergh Van Den B, Corine V, Albert H, Daniëlle H, Ben Willem M. High acceptability of a modified lavage device for self-sampling. Abstract IPV Conference Berlin 2012,
29. Jones HE, Brudney K, Sawo DJ, Lantigua R, Westhoff CL. The Acceptability of a Self-Lavaging Device Compared to Pelvic Examination for Cervical Cancer Screening Among Low-Income Women. J Womens Health (Larchmt) 2012, 21:1275-1281.
30. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40:779-787. 10.1128/JCM.40.3.779-787.2002, 120256, 11880393.
31. Hesselink AT, Heideman DA, Steenbergen RD, Coupe VM, Overmeer RM, Rijkaart D. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011, 17:2459-2465. 10.1158/1078-0432.CCR-10-2548, 21389098.
32. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008, 98:646-651. 10.1038/sj.bjc.6604162, 2243156, 18182990.